DXB everyone knows is super under value based on the deals we've received so far and the market size..
But can we actually get an answer or a understanding about the 144 patients by mid 2025.. I am a holder for a long time but i've heard this a few times and i'm yet to get an answer from anybody about how they will end up getting their patients to 144 with the rate they're going and 286 after that...Mongoose has a point they are behind... can someone explain a bit better how exactly they get results by mid next year if they're only 70% of the way to getting 144 patients
Ann: Dimerix presentation at Bioshares Biotech Summit, page-46
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.0¢ |
Change
-0.040(8.16%) |
Mkt cap ! $250.7M | |||
| Open | High | Low | Value | Volume |
| 48.5¢ | 48.5¢ | 44.8¢ | $1.098M | 2.375M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 337999 | 45.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 46.0¢ | 17466 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| DXB (ASX) Chart |